PET and SPECT Imaging in Psychiatric Disorders
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Objectives: To review recent findings from positron emission tomography (PET) and single photon emission computed tomography (SPECT) studies that investigate the pathophysiology and treatment of schizophrenia, depression, and dementia. Methods: We carried out a review of the literature. Results: PET and SPECT studies have provided evidence of dopamine system dysregulation in patients with schizophrenia and variable loss of monoamines in patients with depression. Antipsychotic response has been demonstrated to be associated with blockade of dopamine D 2 receptors, and antidepressant response has now been linked to blockade of serotonin transporter receptors. PET and SPECT have been extensively evaluated as diagnostic procedures for dementia. Substantial progress has been made in developing radioligands that bind to amyloid deposits in the brain, which should provide new opportunities for early diagnosis and treatment monitoring in Alzheimer's disease. Conclusion: Advances in PET and SPECT imaging have provided new insights into the biology of major psychiatric disorders and their treatment. In the future, we can expect that these imaging techniques will become more central to the management of psychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R., & Van Hoesen, G. W. (1991) · Cerebral Cortex · doi:10.1093/cercor/1.1.103 · Cited by 1,380
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Self-citationTau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037 · cited 1×
“For example, radiotracers specific for NFTs and for different conformations of tau proteins could help differentiate AD from other tauopathies underlying some of the FLD syndromes.(101,119) As the number of people who are entering the age of risk for dementia increases, it will become increasingly important to have ac…”
BackgroundIncreased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020
Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review
Laruelle, M. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200003000-00001 · Cited by 944
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease
Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L. A., McKeel, D. W., & Morris, J. C. (2001) · Neurology · doi:10.1212/wnl.56.1.127 · Cited by 720
Pruessner, J. C., Champagne, F., Meaney, M. J., & Dagher, A. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3422-03.2004 · Cited by 709
Morris, J. C., Storandt, M., McKeel, D. W., Rubin, E. H., Price, J. L., Grant, E. A., & Berg, L. (1996) · Neurology · doi:10.1212/wnl.46.3.707 · Cited by 603
Meyer, J. H., Ginovart, N., Boovariwala, A., Sagrati, S., Hussey, D., Garcia, A., Young, T., Praschak-Rieder, N., Wilson, A. A., & Houle, S. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1209 · Cited by 585
Self-citationMark, R. J., Pang, Z., Geddes, J. W., Uchida, K., & Mattson, M. P. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-03-01046.1997 · Cited by 551
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 4×
“This 80% striatal 5-HT transporter occupancy occurs at minimum clinical dosages despite the hundredfold range in affinity of the 5 SSRIs for the 5-HT transporter.(46) These results demonstrate that, although affinity is an important property of a drug, it cannot predict occupancy, even when plasma levels are known.”
BackgroundInfluentialSelf-citationDoody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Lower dopamine transporter binding potential in striatum during depression
Meyer, J. H., Krüger, S., Wilson, A. A., Christensen, B. K., Goulding, V. S., Schaffer, A., Minifie, C., Houle, S., Hussey, D., & Kennedy, S. H. (2001) · Neuroreport · doi:10.1097/00001756-200112210-00052 · Cited by 269
Self-citationDysfunctional Attitudes and 5-HT2 Receptors During Depression and Self-Harm
Meyer, J. H., McMain, S., Kennedy, S. H., Korman, L., Brown, G. M., DaSilva, J. N., Wilson, A. A., Blak, T., Eynan-Harvey, R., Goulding, V. S., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.90 · Cited by 264 · cited 3×
“pessimism.(51) These findings suggest that particular symptoms of depression, rather than the diagnosis of depression per se, reflect lowered levels of different mononamines in the brain.”
BackgroundResultSelf-citationAbi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179 · cited 2×
“Three main hypotheses have been proposed to account for the superiority of clozapine, each of which is predicated on a body of clinical PET and SPECT research: 5-HT2–D2, loose binding, and regional specificity.(20)”
BackgroundRegional distribution of serotonin transporter protein in postmortem human brain
Kish, S. J., Furukawa, Y., Chang, L.-J., Tong, J., Ginovart, N., Wilson, A., Houle, S., & Meyer, J. H. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2004.10.001 · Cited by 179
Self-citationMeyer, J. H., McNeely, H. E., Sagrati, S., Boovariwala, A., Martin, K., Verhoeff, N. P. L. G., Wilson, A. A., & Houle, S. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1594 · Cited by 160
Self-citation
Cited by
Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?
Ross, B. M., Seguin, J., & Sieswerda, L. E. (2007) · Lipids in Health and Disease · doi:10.1186/1476-511x-6-21 · Cited by 275
Carpenter, W. T., Bustillo, J. R., Thaker, G. K., van Os, J., Krueger, R. F., & Green, M. J. (2009) · Psychological Medicine · doi:10.1017/s0033291709990286 · Cited by 99
Deep learning applied to electroencephalogram data in mental disorders: a systematic review
de Bardeci, M., Ip, C. T., & Olbrich, S. (2021) · Biological Psychology · doi:10.1016/j.biopsycho.2021.108117 · Cited by 71
“Driven by the development of sophisticated imaging capabilities like MRI (Lerch et al., 2017), SPECT, and PET (Zipursky et al., 2007) as well as major breakthroughs in genetic research (Smoller et al., 2019) and new neuroscience techniques such as optogenetics (Tye & Deisseroth, 2012), our understanding of the underly…”
Sachdev, P., Andrews, G., Hobbs, M. J., Sunderland, M., & Anderson, T. M. (2009) · Psychological Medicine · doi:10.1017/s0033291709990262 · Cited by 48
“In cases in which structural brain abnormality is not present, functional abnormalities seen on positron or single photon emission tomography or functional magnetic resonance imaging do relate to both the presence and the severity of the disorders (Zipursky et al. 2007).”
BackgroundTakano, H. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00228 · Cited by 34
“This useful tool has revealed aspects of the pathophysiology of various psychiatric disorders, including schizophrenia, and the mechanisms of action of psychotropic drugs sincemonoamines are the primary targets for antipsychotic and antidepressant drugs (1).”
BackgroundMethod
Metadata
- Authors
- Zipursky, R. B., Meyer, J. H., & Verhoeff, N. P.
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2007-03
- Volume
- 52
- Issue
- 3
- Pages
- 146-157
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- OpenAlex
- W51627854
- Cited by
- 93
- References
- 26
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.